# KLOW Stack

> KLOW Stack combines BPC-157, TB-500, GHK-Cu, and KPV to target tissue repair, cell migration, skin-matrix remodeling, and barrier inflammation.

Canonical: https://pepflow.app/stacks/klow-stack/

Broad recovery, skin, and inflammation-support stack combining BPC-157, TB-500, GHK-Cu, and KPV.

Recovery Inflammation Gut repair Muscle repair Skin Hair Anti-aging

[BPC-157](<https://pepflow.app/peptides/bpc-157/>) [TB-500](<https://pepflow.app/peptides/tb-500/>) [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/>) [KPV](<https://pepflow.app/peptides/kpv/>)

## Overview

KLOW is a four-component recovery, skin, and inflammation-support stack built around BPC-157, TB-500, GHK-Cu, and KPV. It is used to frame tissue repair, cell migration, skin-matrix remodeling, gut or barrier inflammation, and post-procedure support in one plan.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/34267654/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/12750433/>)

Its tradeoff is complexity. BPC-157, TB-500, GHK-Cu, and KPV each bring a different rationale, but no controlled human trial establishes the four-peptide KLOW blend as a safer or more effective recovery, skin, or inflammation protocol.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Peptides in this stack

- [BPC-157](<https://pepflow.app/peptides/bpc-157/>) - Endogenous fragment peptide · A gastric pentadecapeptide studied for gut, wound, vascular, and soft-tissue repair biology, with strong animal data but limited human outcomes. · Recovery Inflammation Gut repair +1 · C Preliminary Limited Data

- [TB-500](<https://pepflow.app/peptides/tb-500/>) - Endogenous fragment peptide · A thymosin beta-4 fragment discussed for wound, ocular, cardiac, and soft-tissue repair, with limited direct TB-500 human evidence. · Soft-tissue recovery Inflammation support Muscle repair · C Emerging Limited Data

- [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/>) - Matrikine/copper tripeptide · A well-characterized copper-binding tripeptide best known for topical skin remodeling, with relevant human data and weaker support for injectable or systemic use. · Skin Hair Recovery +2 · B Moderate Moderate Data

- [KPV](<https://pepflow.app/peptides/kpv/>) - Melanocortin pathway peptide · An alpha-MSH-derived anti-inflammatory tripeptide studied in gut, skin, wound, and barrier models, with no established human therapeutic indication. · Inflammation Gut inflammation Skin inflammation +1 · D Limited Limited Data

## Why They're Combined

BPC-157 and TB-500 form the repair base, GHK-Cu adds collagen and matrix-remodeling logic, and KPV adds the compact anti-inflammatory peptide layer. The stack is built for broad recovery, skin quality, gut or barrier irritation, and post-procedure support discussions.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/34267654/>) [\[5\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/12750433/>)

The reason people reach for KLOW is coverage: tissue repair, migration, skin matrix, and inflammatory signaling in one plan. The cost is interpretability, because each added component makes effect, side-effect, and normal-healing attribution less clean.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) For scheduling terminology, read the [peptide stack planning guide](<https://pepflow.app/blog/how-to-stack-peptides/>).

## How They Work Together

The proposed mechanism layers repair signaling, cell migration, matrix remodeling, and inflammation control. BPC-157 and thymosin beta-4 biology sit on the tissue-repair side, GHK-Cu is tied to fibroblast and collagen biology, and KPV is tied to alpha-MSH-derived anti-inflammatory signaling and intestinal inflammation models.[\[3\]](<https://pubmed.ncbi.nlm.nih.gov/21030672/>) [\[5\]](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) [\[8\]](<https://pubmed.ncbi.nlm.nih.gov/3169264/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/18061177/>)

This is a broad biological rationale, not established additive benefit. A four-component stack can sound more complete while also becoming harder to execute, tolerate, and interpret because several components point at overlapping recovery and inflammation signals.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## What the Evidence Shows

The best-supported KLOW claims are component claims. GHK-Cu has topical skin and wound-context evidence, KPV has anti-inflammatory and intestinal-inflammation rationale, and BPC-157 plus TB-500 are mostly supported by preclinical, review-level, or route-specific repair literature.[\[7\]](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) [\[9\]](<https://clinicaltrials.gov/study/NCT07437586>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/18061177/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40756949/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>)

No controlled human study establishes KLOW as an anti-inflammatory recovery protocol, skin protocol, gut-barrier protocol, or injury-healing protocol. The page should be read as combination logic plus evidence boundaries, not proof that more components create a stronger result.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

## Typical Protocol

Common KLOW schedules keep BPC-157 at 250-500 mcg once or twice daily and TB-500 at 2-4 mg per dose, 2-3 times weekly. GHK-Cu stays route-specific: topical cosmetic use often sits around 1-3% once or twice daily, while injectable-style protocols commonly use 1-2 mg per dose.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/34267654/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) [\[6\]](<https://pubmed.ncbi.nlm.nih.gov/26236730/>)

Common KPV oral, sublingual, or injectable protocols use 1-2 mg per dose, once or twice daily. KLOW is easiest to read as a 4-8 week logged block with fixed dosing days, one primary goal, and weekly notes on skin, gut, inflammation, training tolerance, and adverse effects.[\[10\]](<https://pubmed.ncbi.nlm.nih.gov/12750433/>) [\[11\]](<https://pubmed.ncbi.nlm.nih.gov/18061177/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>)

[Full KLOW Stack dosage guide →](<https://pepflow.app/stacks/klow-stack/dosage/>)

## Important Considerations

KLOW is not beginner-friendly. It combines four evidence levels, multiple route questions, and overlapping recovery, skin, gut, and inflammation signals in one plan. The stack has no controlled human outcome evidence, so it should not be read as proof that more components create a stronger result.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[13\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)

The most practical safeguards are sequencing and monitoring. Define the goal, route, dose, and stop point for each component before starting; fixed-ratio blends make that harder. Product quality, copper exposure, inflammatory markers, GI symptoms, and adverse effects should be tracked, and tested athletes should treat broad recovery-peptide stacks as anti-doping risk areas unless formally cleared.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/40756949/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) [\[14\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) For preparation terminology, read the [mixing versus co-scheduling explainer](<https://pepflow.app/blog/can-you-mix-peptides-together/>).

## Published research 14 sources

- [Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.](<https://pubmed.ncbi.nlm.nih.gov/34267654/>) - \[1\] · PubMed / Frontiers in Pharmacology, 2021. review.

- [Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.](<https://pubmed.ncbi.nlm.nih.gov/40756949/>) - \[2\] · PubMed / HSS Journal, 2025. review.

- [The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.](<https://pubmed.ncbi.nlm.nih.gov/21030672/>) - \[3\] · PubMed / Journal of Applied Physiology, 2011. in vitro.

- [Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications.](<https://pubmed.ncbi.nlm.nih.gov/22074294/>) - \[4\] · PubMed / Expert Opinion on Biological Therapy, 2012-01. review.

- [Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent.](<https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/>) - \[5\] · PMC / Clinical Ophthalmology, 2007. review.

- [GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.](<https://pubmed.ncbi.nlm.nih.gov/26236730/>) - \[6\] · PubMed / BioMed Research International, 2015. review.

- [Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin.](<https://pubmed.ncbi.nlm.nih.gov/16847171/>) - \[7\] · PubMed / Archives of Facial Plastic Surgery, 2006. human clinical.

- [Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.](<https://pubmed.ncbi.nlm.nih.gov/3169264/>) - \[8\] · PubMed / FEBS Letters, 1988. in vitro.

- [Topical GHK-Cu Gel for Acute Skin Wound Healing](<https://clinicaltrials.gov/study/NCT07437586>) - \[9\] · ClinicalTrials.gov, 2026. clinical trial registry.

- [Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.](<https://pubmed.ncbi.nlm.nih.gov/12750433/>) - \[10\] · The Journal of pharmacology and experimental therapeutics, 2003 Aug. review.

- [PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.](<https://pubmed.ncbi.nlm.nih.gov/18061177/>) - \[11\] · Gastroenterology, 2008 Jan. review.

- [Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.](<https://pubmed.ncbi.nlm.nih.gov/41966639/>) - \[12\] · PubMed / Sports Medicine, 2026. review.

- [Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) - \[13\] · U.S. Food and Drug Administration, 2026-04-22. regulatory.

- [The 2026 List of Prohibited Substances and Methods](<https://ita.sport/resource/wada-2026-prohibited-list/>) - \[14\] · World Anti-Doping Agency, 2026. regulatory.

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/#guide-coverage>)

## Quick facts

**Components**

[BPC-157](<https://pepflow.app/peptides/bpc-157/>) Preliminary [TB-500](<https://pepflow.app/peptides/tb-500/>) Emerging [GHK-Cu](<https://pepflow.app/peptides/ghk-cu/>) Moderate [KPV](<https://pepflow.app/peptides/kpv/>) Limited

**Citations**

[14 sources](<https://pepflow.app/stacks/klow-stack/#published-research>)

**Updated**

Aug 17, 2026

### Potential benefits

- Recovery
- Inflammation
- Gut repair
- Muscle repair
- Skin
- Hair

## Related

- [BPC-157 Peptide](<https://pepflow.app/peptides/bpc-157/>)
- [TB-500 Peptide](<https://pepflow.app/peptides/tb-500/>)
- [GHK-Cu Peptide](<https://pepflow.app/peptides/ghk-cu/>)
- [KPV Peptide](<https://pepflow.app/peptides/kpv/>)
